Showing results (1-10 of 205) with videos related to
Sort By:
Pageof 21
British Journal of Cancer|July 14, 2018
Can we establish a hierarchy among trastuzumab biosimilar candidates?Xavier Pivot, Thierry PetitMedecine Sciences : M/S|January 7, 2020
[Biosimilars antibodies: positioning compared to originators - the experience in rheumatology and the biosimilars of trastuzumab in oncology]Xavier Pivot, Philippe GoupilleEuropean Journal of Cancer (Oxford, England : 1990)|April 9, 2008
The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumabMichel Marty, Xavier PivotClinical Breast Cancer|May 19, 2007
Efficacy and safety of ixabepilone, a novel epothilone analogueXavier Pivot, Armelle Dufresne, Christian VillanuevaJournal of Controlled Release : Official Journal of the Controlled Release Society|April 19, 2026
Engineering the subcutaneous delivery of antibody-drug conjugatesAlexandre Detappe, Maria Gutierrez Blanco, Xavier PivotBulletin Du Cancer|February 29, 2008
[Efficacy and safety of ixabepilone (BMS-247550), a novel epothilone B analogue]Cristian Villanueva, Armelle Dufresne, Xavier Pivot, et al.Current Opinion in Otolaryngology & Head and Neck Surgery|March 23, 2006
Is there still a role for triple endoscopy as part of staging for head and neck cancer?Emmanuel Guardiola, Loïc Chaigneau, Christian Villanueva, et al.Future Oncology (London, England)|June 22, 2018
Milestones over the development of SB3, a trastuzumab biosimilarXavier Pivot, Igor Bondarenko, Thiery Petit, et al.European Cytokine Network|July 9, 2002
Impact of glycosylation on the effect of cytokines. A special focus on oncologyAnne-Laure Chamorey, Nicolas Magné, Xavier Pivot, et al.Cancer Journal (Sudbury, Mass.)|October 15, 2009
Response rates: a valuable signal of promising activity?Xavier Pivot, Antoine Thierry-Vuillemin, Cristian Villanueva, et al.Pageof 21